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Glutathione transferase Omega 1 (GSTO1-1) is an atypical GST reported to play a pro-infammatory role in
response to LPS. Here we show that genetic knockout of Gsto1 alters the response of mice to three distinct
infammatory disease models. GSTO1-1 defciency ameliorates the inflammatory response stimulated by LPS
and attenuates the infammatory impact of a high fat diet on glucose tolerance and insulin resistance. In
contrast, GSTO1-1 defcient mice show a more severe inflammatory response and increased escape of bacteria
from the colon into the lymphatic system in a dextran sodium sulfate mediated model of infammatory bowel
disease. These responses are similar to those of TLR4 and MyD88 defcient mice in these models and confrm
that GSTO1-1 is critical for a TLR4-like pro-infammatory response in vivo. In wild-type mice, we show that a
small molecule inhibitor that covalently binds in the active site of GSTO1-1 can be used to ameliorate the
infammatory response to LPS. Our fndings demonstrate the potential therapeutic utility of GSTO1-1
inhibitors in the modulation of infammation and suggest their possible application in the treatment of a range
of inflammatory conditions.
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GSTO1-1 plays a pro-inflammatory 
role in models of inflammation, 
colitis and obesity
Deepthi Menon1,2, Ashlee Innes1, Aaron J. Oakley3, Jane E. Dahlstrom4, Lora M. Jensen1,  
Anne Brüstle1, Padmaja Tummala1, Melissa Rooke1, Marco G. Casarotto1, Jonathan B. Baell  5,8, 
Nghi Nguyen  5, Yiyue Xie5, Matthew Cuellar  6, Jessica Strasser  6, Jayme L. Dahlin7,  
Michael A. Walters  6, Gaetan Burgio  1, Luke A. J. O’Neill2 & Philip G. Board  1
Glutathione transferase Omega 1 (GSTO1-1) is an atypical GST reported to play a pro-inflammatory 
role in response to LPS. Here we show that genetic knockout of Gsto1 alters the response of mice 
to three distinct inflammatory disease models. GSTO1-1 deficiency ameliorates the inflammatory 
response stimulated by LPS and attenuates the inflammatory impact of a high fat diet on glucose 
tolerance and insulin resistance. In contrast, GSTO1-1 deficient mice show a more severe inflammatory 
response and increased escape of bacteria from the colon into the lymphatic system in a dextran 
sodium sulfate mediated model of inflammatory bowel disease. These responses are similar to those 
of TLR4 and MyD88 deficient mice in these models and confirm that GSTO1-1 is critical for a TLR4-like 
pro-inflammatory response in vivo. In wild-type mice, we show that a small molecule inhibitor that 
covalently binds in the active site of GSTO1-1 can be used to ameliorate the inflammatory response to 
LPS. Our findings demonstrate the potential therapeutic utility of GSTO1-1 inhibitors in the modulation 
of inflammation and suggest their possible application in the treatment of a range of inflammatory 
conditions.
Omega class glutathione transferases (GSTOs) are members of the cytosolic glutathione transferase (GST) super 
family but have distinct structural and functional attributes that allow them to perform novel roles that are unre-
lated to the functions of other GSTs1,2. While Omega class GSTs have been found to be highly expressed in some 
tumours, and have been proposed as an anti-cancer drug target, other studies have implicated Omega GSTs as 
determinants of the age at onset of Alzheimer’s disease and have suggested a pro- inflammatory role for GSTO1-1 
in Toll-like receptor 4 (TLR4) linked inflammation2–6.
The Omega class GSTs are distinct from the other GST classes because of their active site cysteine residue 
and their capacity to catalyse several redox reactions that are not catalysed by most other GST isoenzymes1,2. 
GSTO1-1 has been shown to catalyse glutaredoxin (thioltransferase) reactions1 as well as the reduction of methyl-
ated arsenic species7,8, dehydroascorbic acid1,7 and S-phenacylglutathiones9. In a recent development, our studies 
have shown that GSTO1-1 can also catalyse the deglutathionylation of proteins10. This may be its most physiolog-
ically significant role since glutathionylation has been shown to regulate the activity of a varied array of proteins 
and it has been proposed as a mechanism for the regulation of signaling pathways10–12.
In mammals, the initial response to invading pathogens is mounted by the innate immune system. Immune 
cells such as macrophages, neutrophils and dendritic cells express receptors on their cell surface that recognize 
a range pathogen components collectively termed pathogen-associated molecular patterns (PAMPS)13,14. The 
response of immune cells to PAMPS can involve the production of reactive oxygen species (ROS), inflammatory 
cytokines and changes in cellular metabolism to increase glycolysis and decrease oxidative phosphorylation15,16. 
1John Curtin School of Medical Research, Australian National University, Canberra, ACT 2600, Australia. 2School of 
Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland. 3School 
of Chemistry, University of Wollongong, Wollongong, NSW, 2522, Australia. 4ACT Pathology and ANU Medical 
School, The Canberra Hospital, Garran, ACT 2605 Australia. 5Monash Institute of Pharmaceutical Sciences, Monash 
University, Parkville, Victoria, 3052, Australia. 6Institute for Therapeutics Discovery and Development, University 
of Minnesota, Minneapolis, MN, USA. 7Department of Pathology, Brigham and Women’s Hospital, Boston, MA, 
USA. 8School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 211816, People’s Republic of China. 
Correspondence and requests for materials should be addressed to P.G.B. (email: Philip.Board@anu.edu.au)
Received: 11 May 2017
Accepted: 1 December 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIeNTIfIC RepORts |  (2017) 7:17832  | DOI:10.1038/s41598-017-17861-6
The excessive production of ROS in the inflammatory response can cause tissue damage that is a critical factor in 
sepsis and the progression of inflammatory diseases17. Recent studies have implicated GSTO1-1 in a critical role 
in the pro-inflammatory response of macrophages to bacterial lipopolysaccharide (LPS) that is mediated through 
TLR46,18. In those investigations GSTO1-1 expression was knocked down in mouse J774.1 A macrophages by 
shRNA. The GSTO1-1 deficient cells failed to up-regulate NADPH oxidase 1 expression and produce ROS after 
LPS stimulation6. In metabolic studies, GSTO1-1 deficient macrophage cells stimulated with LPS did not produce 
excess lactate or dephosphorylate adenosine monophosphate kinase (AMPK) a key metabolic stress regulator18. 
Unlike normal macrophages challenged with LPS, GSTO1-1 deficient macrophages did not accumulate succinate 
or stabilize HIF1α, typical responses that play significant roles in maintaining the pro-inflammatory state of 
activated macrophages16,18.
To investigate the role of GSTO1-1 in inflammatory pathways in vivo we have characterized Gsto1 knockout 
mice and investigated their response to several inflammatory disease models, including inflammatory shock 
from LPS, dextran sodium sulfate mediated colitis and a pro-inflammatory high fat diet. We also investigated the 
interaction of a small molecule inhibitor with GSTO1-1 and demonstrated that it attenuated the inflammatory 
response of mice to LPS. Overall these studies indicate that GSTO1-1 plays a pro-inflammatory role in the innate 
immune system and our identification of the mechanism of action of a small molecule inhibitor and demonstra-
tion of its capacity to ameliorate LPS mediated inflammatory shock in mice validates GSTO1-1 as a new target 
and paves the way for the further development of novel anti-inflammatory drugs.
Results
Characterizing GSTO1-1 deficiency in Gsto1−/− mice. Immunoblotting of liver extracts revealed that 
GSTO1-1 was absent in Gsto1−/− mice while heterozygous (Gsto1+/−) mice expressed approximately half the 
amount detected in wildtype mice (Fig. 1a). To further confirm that the expression of GSTO1-1 was completely 
absent, the enzyme activity of GSTO1-1 with the specific substrate 4-NPG was found to be undetectable in the 
liver of Gsto1−/− mice (Fig. 1b) while heterozygotes exhibited half the activity measured in wildtype mice. The 
general characteristics of Gsto1−/− mice including body weight and organ weights were determined to evaluate 
whether GSTO1-1 deficiency caused any developmental/growth abnormalities. As shown in Fig. 1c, the total 
body weight of Gsto1−/− mice (8 weeks of age, males) clustered well within the limits set by wildtype littermates. 
Furthermore, the major organs were visually normal and the organ weights did not differ from the wild-type con-
trols (Fig. 1d), suggesting there are no major organ deformities in the Gsto1−/− mice under normal physiological 
conditions. Histological examination of liver, kidney, heart and lungs by light microscopy of H&E sections did 
not reveal any significant differences between wildtype and Gsto1−/− mice (data not shown). The mean values for 
serum alanine aminotransferase (ALT) (WT 2.9 ± 0.3U vs KO 4.3 ± 1.2U) and creatinine (WT 74.5 ± 2.7 µg/dL 
vs KO 80.2 ± 3.7 µg/dL) in 6 wild-type and 6 Gsto1−/− mice did not differ significantly supporting the view that 
liver and kidney function were normal.
Expression profile of glutathione transferases in Gsto1−/− mice. Previously studies of Gstz1 knock-
out mice revealed an increase in the expression levels of other GSTs in response to the increased oxidative stress 
in mice that are deficient in glutathione transferase Zeta19. Given the reduction reactions catalysed by GSTO1-1 
we determined whether Gsto1−/− mice showed a compensating increase in the expression of other GSTs and 
redox sensitive enzymes. Liver lysates were extracted and cytosolic proteins were separated by SDS PAGE and 
immunoblotted with specific antiserum. These blots revealed a significant (p < 0.05) decrease in the expression 
of GSTA1/2, and GSTM2 (lower band) (Fig. 1e–g). However, the expression of GST subunits such as GSTP1, 
GSTK1, GSTO2, GSTT1 and GSTT2 in Gsto1−/− mice was the same as that in the wildtype mice. The expres-
sion levels of NAD(P)H: quinone oxidoreductase 1 (NQO1), considered a good indicator of oxidative stress in 
cells and a target of Nrf2 redox dependent regulation, was also found to be significantly (p < 0.05) lower in the 
Gsto1−/− mice (Fig. 1e,h). The differences observed in GST and NQO1 expression levels between Gsto1−/− and 
wild-type mice were similar in male and female mice. The results suggest that deficiency of GSTO1-1 does not 
result in the compensatory induction of other GSTs and the diminished expression of NQO1 in Gsto1−/− mice 
further suggests that GSTO1-1 deficiency does not give rise to increased oxidative stress.
Hematological changes associated with GSTO1-1 deficiency. To further characterize the impact 
of GSTO1-1 deficiency, the hematological profile of Gsto1−/− mice was evaluated in 8-week-old mice (n = 10) 
(Table 1). There were no significant differences in the red blood cell indices of wildtype and Gsto1−/− mice. 
Although WBCs including basophils, neutrophils and lymphocytes were similar in wild-type and Gsto1−/− mice, 
the monocyte and eosinophil counts of Gsto1−/− mice were significantly (P ≤ 0.05) lower than their wild-type 
counterparts. Monocytes differentiate into resident macrophages in tissues, and exacerbate inflammation20. The 
lower monocyte and eosinophil counts in the Gsto1−/− mice under normal physiological conditions suggests that 
there may be a defect in the differentiation of myeloid cells or possibly a change in the turnover or sequestration 
macrophages that warrants further investigation.
Gsto1−/− mice are resistant to LPS induced inflammatory shock. In previous studies we found that 
GSTO1-1 deficient macrophages do not develop a pro-inflammatory phenotype when challenged with LPS6,18. 
In the present in vivo study, LPS responsiveness was investigated in vivo by monitoring the body temperature and 
survival of age matched male Gsto1−/−, Gsto1+/− and wild-type Gsto1+/+ mice after an ip injection of LPS. At a 
dose of 10 mg LPS/kg the wild-type mice showed marked hypothermia and all wild-type mice reached an adverse 
clinical score and ethical surrogate marker of death within 15 hours post LPS injection. In contrast the knock out 
mice showed high resistance to LPS induced inflammatory shock with minimal changes in body temperature and 
100% survival (Fig. 2a,b KO vs WT p < 0.001). Interestingly, although the Gsto1+/− mice responded adversely to 
www.nature.com/scientificreports/
3SCIeNTIfIC RepORts |  (2017) 7:17832  | DOI:10.1038/s41598-017-17861-6
LPS they were less sensitive than wild-type mice and presented an intermediate response in their body temper-
ature (Het vs WT p < 0.01). The intermediate response of Gsto1+/− mice suggests that even partial deficiency of 
Figure 1. The characteristics of GSTO1-1 deficiency in mice. (a) An immunoblot showing the absence of 
GSTO1-1 protein in the liver of Gsto1−/− mice. (b) GSTO1-1 enzymatic activity with 4NPG as a substrate is 
absent in the liver of Gsto1−/− mice (n = 7). (c) The body weight of 8 weeks old male Gsto1+/+ and Gsto1−/− 
mice, (Mean ± SE n = 8). (d) There were no differences in the weights of the major organs from Gsto1+/+ and 
Gsto1−/− mice (Mean ± SE n = 8). (e) Immuno blots of GST proteins and NQO1 in Gsto1+/+ and Gsto1−/− mice. 
(f–h) Quantitative comparison of GSTA1/2, GSTM2, and NQO1levels normalized to actin (Mean ± SE n = 4). 
(*p < 0.05, **p,0.01).
www.nature.com/scientificreports/
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GSTO1-1 can protect against LPS mediated inflammatory shock. The similar response of female mice is shown 
in Supplementary Fig. S1.
Pathological changes associated with GSTO1-1 deficiency and LPS exposure. Histological 
examination of the liver from mice treated with 50 mg LPS/kg (n = 3/time period) resulted in patchy acute hepati-
tis with focal necrosis after 1 hour in wild-type mice. In contrast this pathology was completely absent in Gsto1−/− 
mice up to 12 hours post LPS (shown after 3 hours in Fig. 2c,d). Histological examination of the spleen from mice 
treated with 50 mg LPS/kg (n = 3/time period) revealed a variable number of tingible body macrophages, mainly 
in the white pulp areas, in wild type mice at 1, 3 and 6 hours post LPS (Fig. 2e). In the red pulp, areas of acute 
inflammation were apparent in wild-type mice 3 hours post LPS treatment (Fig. 2e). This was in contrast to the 
Gsto1−/− mice that presented normal spleen histology for at least 6 hours (Fig. 2f).
Attenuated pro-inflammatory cytokine expression in LPS treated Gsto1−/− mice. The response 
of Gsto1−/− mice to LPS was further examined by determining the serum cytokine levels in mice injected with 
50 mg LPS/kg. Wild-type mice produced significantly elevated levels of cytokines TNF-α, IL-6 and IL-1β 30 min-
utes after injection with LPS (Fig. 3a–c). In contrast, the Gsto1−/− mice were less responsive to LPS and produced 
significantly lower levels of all three cytokines when compared with wild type mice (Fig. 3a–c). The change in 
serum cytokine levels in the wild-type mice was similar to the trend in previously published studies21,22. IL-1β 
expression in the spleen was also significantly (p < 0.001) suppressed in Gsto1−/− mice relative to the response of 
wild-type mice (Fig. 3d). A similar suppression of IL-1β expression was also observed in the liver 12 hours after 
LPS treatment (data not shown). The increased survival of Gsto1−/− mice treated with LPS correlates well with 
their suppressed pro-inflammatory cytokine expression and the lack of liver necrosis.
LPS induced NADPH oxidase 1 transcript levels were attenuated in Gsto1−/− mice. Knockdown 
of GSTO1-1 in J774.1 A macrophages has been shown to attenuate the induction of NOX1 and the production of 
ROS by LPS6. In this study NOX1 transcription was significantly (p < 0.001) induced in the spleen of wild-type 
mice 3 hours after injection with 50 mg LPS/kg. Although NOX1 was also induced in LPS treated Gsto1−/− mice 
(Fig. 3e), the levels were significantly (p < 0.05) less than those achieved in wild-type mice. In order to examine 
the direct of impact GSTO1-1 deficiency on ROS expression we determined ROS levels in bone marrow derived 
macrophage (BMDM) cultures after LPS treatment (200 ng/mL for 1 hour). The results indicated a highly sig-
nificant (p < 0.001) attenuation of ROS production in GSTO1-1 deficient BMDMs (Fig. 3f). This confirmed, in 
Gsto1−/− mice, the significant contribution of GSTO1-1 to LPS mediated NOX1 induction and ROS generation 
previously reported in J774.1 A macrophages6.
Gsto1−/− mice are less susceptible to HFD-induced obesity and inflammation. TLR4 and MyD88 
play prominent roles in signaling that supports low level inflammation in obesity. Deficiency of either of these 
proteins attenuates obesity and the metabolic changes that occur in response to a high fat diet (HFD)23,24. Since 
GSTO1-1 appears to play a role in the TLR4 and MyD88 inflammatory pathway, we investigated the response 
of Gsto1−/− mice to a high fat diet. Gsto1−/− mice maintained on a diet containing 23% fat for 13 weeks were 
phenotypically similar to MyD88−/− and TLR4−/− mice fed a similar diet23,24. The Gsto1−/− mice failed to gain 
additional weight when fed a HFD while the wild-type mice gained 1-2 g per week more than chow fed wild-type 
controls (Fig. 4a). On dissection, the amount of abdominal fat in wild-type mice fed the high fat diet was signifi-
cantly greater than that found in the Gsto1−/− mice (p < 0.001) (Fig. 4b,c). The lipid content in isolated adipocytes 
was determined by oil red O staining. As shown in Fig. 4d, the amount of accumulated lipids in high fat diet fed 
Gsto1−/− mice was significantly less (p < 0.001) than that occurring in their wildtype counterparts. Histological 
examination of the abdominal adipose tissue revealed increased inflammation in wild-type mice compared with 
Gsto1−/− mice (Fig. 4e,f). Furthermore, the number of infiltrating activated macrophages (F4/80+) isolated from 
the abdominal white adipose tissue was remarkably higher in the wild-type mice compared to the Gsto1−/− mice 
(Fig. 4i). Examination of the liver revealed more steatosis and acute inflammation in wild-type mice fed a HFD 
compared to Gsto1−/− mice (Fig. 4g,h). Over all this suggests a higher level of inflammation in the wild-type mice. 
Wild-type Gsto1−/−
RBC (x10E06 cells/µL) 11.7 ± 0.23 12.1 ± 0.17
HGB (g/L) 210.5 ± 4.29 211.4 ± 3.95
HCT 0.5 ± 0.01 0.5 ± 0.01
MCV(fL) 45.8 ± 0.5 45.3 ± 0.36
Platelets (x10E03 cells/µL) 923.6 ± 91.65 965 ± 73.27
WBC (x10E03 cells/µL) 10.3 ± 1.06 9.8 ± 0.44
Neutrophils (x10E03 cells/µL) 1.5 ± 0.26 1.7 ± 0.35
Lymphocytes (x10E03 cells/µL) 5.8 ± 1.38 4.6 ± 1.12
Monocytes (x10E03 cells/µL)* 0.3 ± 0.06 0.18 ± 0.03
Eosinophils (x10E03 cells/µL)* 0.2 ± 0.04 0.1 ± 0.02
Basophils (x10E03 cells/µL) 0.02 ± 0.01 0.04 ± 0.01
Table 1. Hematological evaluation of wild-type and Gsto1−/− mice. Mean ± SE n = 10 (*p ≤ 0.05).
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As expected, wild-type mice fed a HFD acquired insulin resistance over the period of the diet and were unable to 
utilize glucose as rapidly as the chow fed mice (Fig. 4j,k). In contrast the HFD/Gsto1−/− mice remained responsive 
to insulin suggesting that they are resistant to HFD induced metabolic distress (Fig. 4j,k).
Gsto1−/− mice show increased susceptibility to dextran sodium sulfate induced colitis. In 
mice, ingestion of dextran sodium sulfate (DSS) induces colitis and a major inflammatory response to the escape 
of microbial flora from the colon. Since our current experiments have shown that Gsto1 deficient mice have 
a defect in LPS stimulated inflammation, we evaluated the development of dextran sulfate mediated colitis in 
Gsto1−/− mice. Mice were treated with a dose of 3.5% DSS in their drinking water for 5 consecutive days followed 
by a 3-day period of receiving regular water. Both wild-type and Gsto1−/− mice demonstrated weight loss though 
the extent of disease progression was significantly exacerbated in the Gsto1−/− mice from day 1. The severity of 
colitis in these mice was evaluated as a clinical score by summing the percentile of weight loss, fecal blood, stool 
consistency and occurrence of blood in the anal orifice (Fig. 5a,b). Gsto1−/− mice scored at an average of 10.6/14 
while the wild-type mice exhibited a less intense response (8/14) 8 days after the initiation of the experiment. 
Since the blood loss associated with colitis induces anemia in colitis patients, we determined the blood hemoglo-
bin levels in Gsto1−/− mice. As shown in Fig. 5c, both the wild-type and Gsto1−/− mice treated with DSS presented 
with a significant drop in their hemoglobin levels (p < 0.01). However, the decrease was more pronounced in the 
Gsto1−/− mice (p < 0.05), complimenting their higher clinical score. The colonic length was also determined as an 
Figure 2. Response of Gsto1−/− mice to LPS. (a) Kaplan-Meyer plot showing survival of male mice treated with 
10 mg/kg LPS (*p < 0.05, **p,0.01). (b) Body temperature of mice treated with LPS, Mean ± SE Gsto1+/+ n = 7, 
Gsto1+/− n = 6, Gsto1−/− n = 5 (*p < 0.05, **p,0.01, ***p < 0.001).The significance of different comparisons 
are indicated as (* −/− vs +/+); († −/− vs +/−); (# +/− vs +/+). The dashed lines indicate times when there 
were too few surviving wild type mice to allow statistical comparison. Mice were ethically euthanazed if the 
decrease in temperature exceeded 10 °C or they reached a predetermined morbidity score. This experiment is 
representative of several experiments undertaken with different LPS concentrations (see Supplementary Fig. S1 
for female mice). (c) liver of wild-type mouse treated with 50 mg/kg LPS for 3 hours demonstrating multiple foci 
of acute inflammation with necrosis (c) yellow arrows) which was absent in the liver of Gsto1−/− mice receiving 
the same LPS treatment (d). (e) spleen histology of wild-type mouse treated with 50 mg/kg LPS for 6 hours 
demonstrating expansion of the white pulp due to accumulation of tingible body macrophages (yellow arrows) 
and increased inflammatory cells in the red pulp (green arrow), insert shows tingible body macrophages, ×630. 
(f) spleen of wild-type mouse treated with 50 mg/kg LPS for 6 hours with normal appearing red and white pulp.
www.nature.com/scientificreports/
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additional measure of the severity of the colitis. The colonic length in wild-type and Gsto1−/− mice receiving reg-
ular drinking water ranged between 8.2 to 10.5 cm and the two groups were not significantly different. However, 
the colonic length in DSS-fed mice was significantly shorter (P < 0.001), than the water-fed mice, and the average 
of the DSS treated Gsto1−/− mice (5.8 ± 0.68 cm) was significantly shorter (P < 0.01) than the average of the DSS 
treated wild-type mice (7.1 ± 0.6 cm) (Fig. 5d,e).
We next examined the gut flora escaping into the mesenteric lymph nodes as an additional measure of dis-
ease severity. Mesenteric lymph nodes that drain the intestine were isolated and cultured in vitro. The number 
of bacterial colonies observed in DSS fed Gsto1−/− mice was significantly higher (P < 0.001) than the number 
counted in the wild-type mice, suggesting that the disease was more severe in the absence of GSTO1-1 (Fig. 5f). 
Histological examination of the distal colon did not reveal any abnormalities in the wild-type or Gsto1−/− mice 
fed water. The DSS treated Gsto1−/− mice developed severe transmural acute colitis with extensive mucosal ulcer-
ation while the DSS treated wild-type mice developed much less severe acute colitis without ulceration (Fig. 5g–j). 
In order to assess the extent of intestinal damage in response to DSS, we examined the rate of proliferation of 
intestinal epithelial cells using multiple markers. Staining for BrdU positive cells in intestinal sections showed 
that DSS treatment caused a significant increase in proliferation of epithelial cells along the colon lining in both 
wild-type and Gsto1−/− mice. However there was no difference in the number of BrdU positive cells in the DSS 
treated Gsto1−/− mice compared to the wildtype counterparts (Fig. 5k,l). In contrast the proliferation markers 
c-myc and Proliferating Cell Nuclear Antigen (PCNA) showed significantly increased expression in DSS treated 
Gsto1−/− mice (Fig. 5m–o). Taken together these data suggest that Gsto1−/− mice are more sensitive to DSS than 
wild type mice and show increased proliferation of intestinal epithelial cells.
ML175 covalently labels to the active site cysteine residue (Cys 32). Given the importance 
of GSTO1-1 in the inflammatory response to LPS and other mouse models of inflammation it is evident that 
GSTO1-1 is a novel target for the development of new anti-inflammatory drugs. In previous studies we have 
shown that the GSTO1-1 inhibitor ML175 can block the expression of NOX1 and the generation of ROS in mac-
rophages after treatment with LPS6. To examine the mechanism underlying the inhibition by ML175 we solved 
the crystal structure of GSTO1-1 in complex with ML175. The overall structure of the GSTO1-1 - ML175 com-
plex is essentially the same as the previously published complex with GSH1. Superposing the structures results 
in a RMSD of 0.36 Å over 237 Cα atoms. ML175 binds in the “H-site” of GSTO1-1 and is covalently attached to 
catalytic residue Cys32. Clear electron density was observed for the nitrophenyl moiety, with weaker density 
observed for the propyltrifluoroacetamide group. The flexible nature of the propyltrifluoroacetamide group may 
explain this observation. The chloride atom of ML175 has been displaced by the sulfur atom of C32. The nitrophe-
nyl moiety is oriented toward the side-chain of Lys57, and sits between Leu56 and Tyr229. The propyltrifluoro-
acetamide moiety lies in an extended conformation oriented toward the back of the “H-site”, contacting residues 
Pro33, Val127, Ile131 and Trp222 (Fig. 6a). Binding of ML175 induced rotation of residues Tyr229 and Ile131 
(Fig. 7b). A water molecule mediates interaction between the side-chains of Arg183, Trp222, the carbonyl oxy-
gen of Phe31, and the carbonyl oxygen of the ML175 propyltrifluoroacetamide moiety (Fig. 6a). The previously 
reported GSTO1-1 inhibitor C1-273 binds in essentially the same pocket as ML175, and like ML175, covalently 
modifies Cys32 (Fig. 6c).
Figure 3. The diminished inflammatory response of Gsto1−/− mice to LPS at 50 mg/kg for 30 minutes, n = 5 
or 6. (a) Serum TNF. (b) Serum IL-6. (c) Serum IL-1β. (d) Spleen IL-1β RNA expression. (e) Spleen NADPH 
oxidase 1(Nox1) RNA expression. (f) ROS production from BMDM treated with 200 ng/mL LPS for 1 hour. 
Data shown as Mean ± SE n = 5 or 6, *P < 0.05, **P < 0.01, ***P < 0.001.
www.nature.com/scientificreports/
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ML175 is not generally thiol-reactive. Given its covalent mechanism of target engagement, we tested 
ML175 by ALARM NMR, an industry-developed heteronuclear multiple-quantum correlation (HMQC) 
counter-screen for nonspecific protein reactivity25,26. ML175 did not perturb the La antigen conformation (see 
Supplementary Fig. S2), suggesting it may not react indiscriminatingly with protein cysteine thiol residues.
ML175 protects mice from LPS induced inflammation. ML175 treated bone marrow derived mac-
rophages (BMDMs) showed a dose dependent decrease in the secretion of IL-6 on LPS stimulation (Fig. 7a). 
This result suggested that ML175 could potentially protect mice against LPS mediated inflammatory shock. Mice 
treated with 50 mg/kg LPS show a dramatic increase in serum IL-6, and TNFα, within 30 minutes (Fig. 7b,c). 
This rapid pro-inflammatory response is significantly attenuated in mice treated with ML175 (Fig. 7b,c). In a 
subsequent proof of principle study, wild type mice pre-treated with a daily ip injection of ML175 20 mg/kg for 3 
days followed by a single intra peritoneal dose of LPS (15 mg/kg) were found to be less susceptible to LPS induced 
inflammation as monitored by body temperature (Fig. 7d) and survival (Fig. 7e). The attenuated inflammatory 
phenotype of ML175 treated mice confirms that ML175 can act as an anti-inflammatory agent by irreversibly 
binding to GSTO1-1. Further studies could usefully examine the pharmacokinetics of ML175, to optimize its 
delivery and evaluate specific target engagement in cells and in vivo.
Figure 4. Response of Gsto1−/− mice to a high fat diet. (a) Weekly weight gain on high fat and normal chow 
diets (Mean ± SE n = 9). (b) Abdominal fat pads from wild type and Gsto1−/− mice after 13 weeks on a high 
fat diet. (c) Weight of abdominal fat after 13 weeks on a high fat diet (p < 0.001 Mean ± SE n = 9). (d) Lipid 
accumulation in isolated adipocytes from Gsto1−/−/HFD mice was significantly less than wildtype/HFD mice 
as quantified by oil red O staining (13 weeks on HFD, Mean ± SE n = 9). After 13 weeks on a high fat diet 
inflammation (green arrows) is seen in adipose tissue in wild-type mice (e) and was often not seen in Gsto1−/− 
mice (f) (circle indicates an adipocyte). More steatosis (yellow circled areas) is present in the livers of the wild-
type mice (g) compared to Gsto1−/− mice (h) after 13 weeks on a high fat diet (green arrow indicates a portal 
tract). (i) The number of adipose tissue associated macrophages is significantly increased in wild type mice 
receiving a high fat diet (p < 0.001 Mean ± SE n = 9). (j) Blood glucose response to a glucose load in mice fed 
a high fat diet (Mean ± SE n = 9). (k) Blood glucose response to insulin in mice fed a high fat diet (Mean ± SE 
n = 9).
www.nature.com/scientificreports/
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Discussion
In previous studies we have shown that GSTO1-1 deficient macrophages have a defect in their pro-inflammatory 
response to LPS6,18. In this study we characterized GSTO1-1 deficient mice and found that they have significant 
defects in their response in several distinct inflammatory models. Although unchallenged GSTO1-1 deficient 
mice appear to be phenotypically normal in most regards, hematological analysis revealed a relative deficiency 
of monocytes and eosinophils. This could possibly contribute to their abnormal responses to pro-inflammatory 
stimuli given the role of macrophages in inflammation. The cause of the relative deficiency of circulating mono-
cytes and eosinophils is not immediately obvious but given the effects of GSTO1-1 deficiency on macrophage 
metabolism18 it is possible that this deficiency could affect the differentiation or survival of these particular cell 
lineages. Noting the many phenotypic similarities between GSTO1-1 deficient mice and mice deficient in TLR4 
or MyD88, we considered the possibility that they may also have a similar hematological phenotype. However, 
there is a paucity of published data on the basic hematology of unchallenged TLR4 or MyD88 deficient mice that 
limits their comparison with GSTO1-1 deficient mice. The observation that MyD88 deficient mice have impaired 
Figure 5. Sensitivity of mice to DSS mediated colitis. (a) Total clinical score comprising weight, stool 
consistency, blood at orifice and fecal blood, after DSS treatment, Mean ± SE n = 10. (b) fecal blood score 
after DSS treatment, Mean ± SE n = 10. (c) Blood hemoglobin after DSS treatment was significantly lower in 
Gsto1−/− mice than in wildtype mice, (p < 0.05 Mean ± SE n = 10). (d,e) Colon length after DSS treatment, 
Mean ± SE n = 10. (f) Number of bacterial colonies escaping to the mesenteric lymph gland after DSS treatment 
is significantly greater in Gsto1−/− mice, (p < 0.001 Mean ± SE n = 10). (g and h) show sections of distal colon 
from water and DSS fed wild-type mice. The wild-type mice fed water showed normal colonic mucosa (g), while 
the DSS fed mice showed mild acute colitis confined to the mucosa and submucosa without ulceration (star 
symbol indicates the submucosal oedema and inflammatory cell infiltrate) (h). (I and J) show sections of distal 
colon from water (I) and DSS fed Gsto1−/− mice (j). While the distal colon from the water fed mice is normal 
the DSS fed Gsto1−/− mice showed severe acute colitis with transmural inflammation with mucosal ulceration 
(yellow brackets shows absence of mucosal epithelium and pus indicative of acute ulceration). (k,l) BrdU 
incorporation into DNA in distal colonic sections was assessed immunohistochemically to evaluate the extent 
of epithelial cell proliferation in response to DSS (Mean ± SE n = 6). (m–o) Cell proliferation was also assessed 
by immunostaining c-myc (n) and PCNA (o) in protein blots from the distal colon (Mean ± SE n = 4). M is a 
representative blot from 2 replicates. *P < 0.05, **P < 0.01, ***P < 0.001.
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monopoiesis during bacterial infection does however suggest that there may be a hematological anomaly that 
warrants further investigation27.
To determine if there was a change in the expression of other GSTs to compensate for the deficiency of 
GSTO1-1 we examined the expression of GSTs from the Alpha, Mu, Pi, Theta, Zeta, Omega and Kappa classes. 
Although GSTO2-2 has the greatest structural and functional similarity to GSTO1-1 and is the most likely 
enzyme to duplicate the functions of GSTO1-1, its expression was unchanged in Gsto1−/− mice. Among the 
other GSTs evaluated we found decreased expression of GSTA1/2 and GSTM2-2. These GSTs are thought to be 
up-regulated by oxidative stress via the Nrf2 signaling pathway. Similarly, Gsto1−/− mice had lower expression 
of NQO1, an enzyme that is also strongly induced by oxidative stress via Nrf2 signaling28,29. Thus, there is no 
evidence to suggest that other GSTs are up regulated to compensate for the GSTO1-1 deficiency and although 
GSTO1-1 catalyses several reduction reactions, the available data suggest that the deficient mice are not the sub-
ject of oxidative stress. This result contrasts with the analysis of gene expression studies of cell lines treated with 
a GSTO1-1 inhibitor (C1-27) where genes with an Nrf2 signature were significantly up regulated3. However, 
it is likely that the physiological situation induced by genetically determined GSTO1-1 deficiency in vivo may 
Figure 6. The structure of GSTO1-1 with ML175. (A) stereo-diagram showing the model of GSTO1-1 with 
ML175 bound to C32. ML175 (grey carbon atoms) and surrounding residues (green carbon atoms) are 
represented in stick form. The backbone of the protein is represented in cartoon form. (b) Stereo-diagram 
showing the active site of GSTO1-1 in complex with ML175 (green) and GSH (purple) superposed. (c) stereo 
diagram showing the active site of GSTO1-1 in complex with ML175 (green) and C1-27 (purple) superposed. 
The backbones of the proteins are represented in cartoon form.
www.nature.com/scientificreports/
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differ significantly from that induced transiently by a small molecule inhibitor that may have additional off-target 
effects3.
The resistance of GSTO1-1 deficient mice to LPS mediated inflammatory shock observed in the present stud-
ies has confirmed in vivo that GSTO1-1 is required for the normal inflammatory response to LPS. GSTO1-1 
deficiency diminished the release of pro-inflammatory cytokines IL6, IL-1β and TNFα, and attenuated the acute 
hepatic pathology that occurs in normal mice exposed to LPS. This phenotype is consistent with the attenuated 
response of TLR4 and MyD88 deficient mice to LPS21,22. The observation that heterozygous mice (Gsto1+/−) that 
express 50% of the normal GSTO1-1 levels are less sensitive to LPS than normal mice suggests that GSTO1-1 
inhibitors would not need to completely inhibit GSTO1-1 to be of value in reducing inflammatory responses 
mediated through TLR4.
The incidence of obesity and type 2 diabetes (T2D) is rapidly increasing and it is a significant global health 
issue. Insulin resistance, a hallmark of T2D is commonly associated with systemic inflammation that is charac-
terized by the elevated production of IL-1β and the activation of pro-inflammatory signaling pathways30. Free 
fatty acids (FFA) are increased in subjects with T2D and they have been shown to induce inflammatory cytokine 
production via TLR4 signaling31,32. Consequently, in mouse models, the consumption of a high fat diet can result 
in obesity and high levels of circulating FFA that can induce inflammation and insulin resistance. Multiple studies 
have reported that TLR4 deficiency attenuates obesity and insulin resistance in mice32–37. In the present investi-
gation, we found that GSTO1-1 deficient mice consuming a high fat diet present a similar phenotype to that of 
TLR4 and MyD88 deficient mice23,24 and do not exhibit marked obesity and insulin resistance. Several studies 
have attributed the macrophage-induced impairment of insulin signaling in T2D to the release of IL-1β38,39. Our 
observation of diminished IL-1β expression in the serum and spleen of GSTO1-1 deficient mice treated with LPS 
therefore reveals a possible mechanism by which GSTO1-1 deficiency attenuates insulin resistance in mice on a 
high fat diet. This result again confirms the critical role played by GSTO1-1 in pro-inflammatory signaling and 
suggests the possibility that GSTO1-1 inhibitors may be of value in the treatment of T2D since IL-1β inhibitors 
have already been found to be effective in modulating insulin resistance38,39.
Since luminal bacterial flora are thought to be an important trigger in the development of inflammatory bowel 
disease, there have been extensive investigations into the role of TLR4 signaling and the innate immune sys-
tem in the etiology of colitis (reviewed in40) and polymorphisms in NOD2 and TLR4 have been associated with 
increased susceptibility to Crohn’s disease41,42. Deficiency of TLR4 and MyD88 have been shown to sensitize and 
mice to DSS mediated colitis and previous studies have concluded that TLR4 and MyD88 are required for the con-
trol of bacterial translocation and triggering the repair of the intestinal epithelium43–45. Our current results with 
GSTO1-1 deficient mice showing increased clinical severity of colitis, increased escape of bacteria from the colon 
and increased epithelial cell replication indicate that GSTO1-1 deficient mice follow a similar clinical course in 
the DSS colitis model to that occurring in TLR4 and MyD88 deficient mice.
Figure 7. ML175 suppresses the inflammatory response to LPS. (a) ML175 dose dependent suppression of IL-6 
secretion from LPS treated BMDMs, Mean ± SE n = 3. (b) Serum IL-6 in mice treated with LPS (50 mg/kg) and 
ML175 (10 mg/kg) (Mean ± SE n = 5 or 6, *P < 0.05). (c) Serum TNFα in mice treated with LPS (50 mg/kg) 
and ML175 (20 mg/kg), (Mean ± SE n = 6 **P < 0.01). (d) Change in temperature after ip LPS injection (15 mg/
kg) and treatment with ML175 10 mg/kg at −48, −24, and −2 hours prior to LPS, Mean ± SE n = 7. The dashed 
lines indicate times when there were too few surviving wild type mice to allow statistical comparison.
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Thus, in the models of inflammation that we have investigated, we have consistently observed a phenotype 
similar to that of TLR4 deficient or MyD88 deficient mice, strongly confirming the view that GSTO1-1 makes a 
significant contribution to pro-inflammatory signaling via the TLR4 pathway. Previous published studies with 
the TLR3 ligand Poly IC6 and our unpublished studies with ligands such as PAM3CSK4, R848 and CpG have 
indicated that GSTO1-1 is not required for pro-inflammatory signaling through TLR1/2, TLR3, TLR7 or TLR9.
Our crystallographic study demonstrated that the GSTO1-1 inhibitor ML175 binds in the active site and 
forms a covalent bond with the sulfur atom of the active site cysteine (C32). The formation of this covalent com-
plex results in the irreversible inactivation of GSTO1-1. In a proof of concept study we found that ip injection of 
ML175 in mice attenuated the LPS induced release of pro-inflammatory cytokines (IL-6, TNFα) and provided 
significant protection against the inflammatory shock associated hypothermia caused by LPS. This protection 
was not as profound as that provided by genetic deficiency of GSTO1-1 and may be associated with sub optimal 
bioavailability and receptor occupancy below 100%, but indicates the clear potential of GSTO1-1 inhibitors as 
anti-inflammatory agents.
It is possible that ML175 could itself form the basis of drug development. Although it covalently labels its tar-
get and therefore necessarily has some degree of protein-reactivity, such a mechanism is not uncommon amongst 
FDA-approved drugs46. However, reactivity in drugs is usually designed late in development or discovered ser-
endipitously46 and not inherited from a high throughput screening hit, such as ML175. For this reason, it is 
important to determine that ML175 is not generally protein-reactive, which is why we determined its propensity 
for thiol reactivity using the ALARM NMR assay. The negative readout by ML175 in this assay involving highly 
reactive protein thiols was surprising, but vindicates use of ML175 as a tool for GSTO1-1. Indeed, it has been 
shown that amongst arrays of electrophilic functional groups, chloromethylamides are relatively less reactive and 
may be considered reasonable starting points for optimization47,48.
The glutathionylation/deglutathionylation of proteins is emerging as a significant mechanism regulating pro-
tein function and has been implicated in the regulation of important signaling pathways11,12,49. Monocytes and 
macrophages are key cellular components of the innate immune system and the impact of glutathionylation on 
macrophage function and inflammation has been recently reviewed50–52. Significantly, TNFα release, HIF1α sta-
bilization, STAT3 phosphorylation and Caspase 1 activation in macrophages have all been shown to be regulated 
by redox potential and glutathionylation52. GSTO1-1 catalyses the deglutathionylation of protein thiols and could 
therefore play a significant role in modulating the glutathionylation of intracellular proteins that participate in 
specific signaling pathways10. The attenuation of the inflammatory response to LPS by the administration of the 
GSTO1-1 inhibitor ML175 indicates that the enzymatic activity of GSTO1-1 is required for its pro-inflammatory 
role further suggesting that the glutathionylation of a key protein in the TLR4 pro-inflammatory pathway may 
act as a regulatory switch.
This study has identified GSTO1-1 as a novel target for the development of drugs for the treatment of inflam-
mation mediated via TLR4 and possibly the treatment of the inflammation associated with obesity. The suitability 
of GSTO1-1 as a drug target is enhanced by the observation that mice heterozygous for GSTO1-1 deficiency show 
partial protection against LPS mediated inflammation suggesting that complete pharmacological inhibition of 
GSTO1-1 may not be required to achieve a significant response. The value of GSTO1-1 as a target is also enhanced 
by the observation that homozygous GSTO1-1 deficient mice do not exhibit any overt pathology. Thus pharma-
cologically induced GSTO1-1 deficiency may have few side effects apart from those potentially induced by off 
target effects of the inhibitor. Importantly the absence of any adverse effects arising from GSTO1-1 deficiency is 
also apparent in humans. Although several GSTO1alleles that encode unstable enzyme variants occur in human 
populations, no cases of GSTO1-1 deficiency with a deleterious phenotype have been reported2,53. Additional 
benefits to be gained by the use of small molecule inhibitors of GSTO1-1 to regulate the expression of IL-1β 
include their low cost of production and their potentially short half-life relative to biologics such as canakinumab 
and rilonacept would allow their rapid withdrawal if a severe infection occurred.
Methods
Animals. Gsto1 knockout mice were supplied by Taconic Biosciences (U.S.A), Model TF1210 Gsto1/
NM_010362. The mice were generated by the deletion of a 347 bp fragment containing exons 1 and 2 of the 
Gsto1 gene in 129/SvEv ES cells. The ES cells were subsequently injected into C57BL6/albino embryos. The strain 
was subsequently back crossed to C57BL6 (Charles River) mice and genotyping was undertaken by PCR using 
primers designed by Taconic. Heterozygotes were mated to generate knockout and wildtype control littermates. 
In most cases mice were 8 weeks of age when selected for an experiment. Mice were maintained at the ANU 
Biosciences facility under controlled animal room conditions. The animals were fed regular animal diet and water 
ad libitum. All experiments were undertaken under protocols approved by the ANU Animal Experimentation 
Ethics Committee according to Guidelines provided by the Australian National Health and Medical Research 
Committee.
Reagents and antibodies. All reagents were purchased from Sigma unless indicated otherwise. All GST 
antibodies were generated in house from recombinant antigens or were gifts from colleagues as previously 
reported54. The GSTO1-1 inhibitor ML175 was prepared by previously described methods55.
Immunoblotting. SDS-PAGE and non-reducing SDS-PAGE were performed as described previously56. 
Separated proteins were transferred onto nitrocellulose membranes57 and immunodetected using primary anti-
bodies at a 1:1000 dilution and probed with a goat anti-rabbit IgG horseradish-peroxidase-conjugated secondary 
antibody (Dako). Chemiluminescence was detected by the ECL Rapid Step chemiluminescence detection system 
(Calbiochem, Merck, Germany).
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S-(4-nitrophenacyl)glutathione (4-NPG) reduction. GSTO1-1specific activity was determined with 
4-NPG as described previously58. Briefly, 5 mM 4-NPG was incubated with 75 μg of cell lysate protein in 100 mM 
Tris, pH8.0, 1.5 mM EDTA and 10 mM β-mercaptoethanol. The reduction of 4-NPG was measured spectro-
photometrically at 305 nm at 37 °C and the specific activity was calculated based on an extinction coefficient of 
1.1 mM−1 cm−1.
In vivo  temperature measurements. Mouse body temperature was determined with 
temperature-recording probes (DAS-7009 smart reader, BMDS) that were implanted sub-cutaneously oriented 
longitudinally above the shoulder 24 hours prior to LPS injections. The body temperature was monitored over 
24 hours to confirm that no infection occurred due to the insertion of the probe. For LPS experiments, body 
temperature of less than 24 °C was considered as an ethical surrogate marker of death and mice were euthanized 
immediately by CO2 asphyxiation in accordance with the ANU animal ethics protocol.
Organ collection and homogenization. Organs were harvested in assay specific buffers. For immu-
noblots and biochemical assays, tissues were dissected, washed in PBS and homogenized in T-PER (Thermo 
Scientific) using an Ultraturux homogenizer. Homogenates were centrifuged at 20000 × g at 4 °C to remove tissue 
debris and stored at −20 °C until further use.
Hematology. Blood was collected into heparin-coated sterile tubes by retro-orbital bleeding from 8 week 
old mice. Differential cell counts were immediately analysed using an ADVIA Haematology systems instru-
ment (Siemens). Hemoglobin determinations in the colitis model were undertaken on blood samples collected 
in EDTA coated tubes. Briefly, blood was added to Drabkin’s solution (100 mg/L sodium cyanide, 300 mg/L of 
potassium ferricyanide) in a 1:20 ratio and absorbance was read at 540 nm after 5 minutes and compared with a 
standard curve.
Real time RT-PCR. Total RNA was extracted from cells and tissues in trizol as per manufacturer’s instruc-
tions (Invitrogen). Trizol-lysed samples were incubated for 5 minutes at room temperature and passed repeatedly 
through a 25-gauge syringe/needle to enhance cell lysis. 200 μl of chloroform was added to each sample and the 
tube was shaken vigorously for 30 seconds. The samples were centrifuged at 15000 × g for 15 minutes at 4 °C 
and the top clear layer was transferred to a fresh tube followed by the addition of 600 μl of 70% ethanol. The 
samples were then transferred to RNA spin columns and RNA was isolated as per manufacturer’s instructions 
(Qiagen RNA extraction kit). The extracted RNA was treated with DNase to remove genomic DNA contamina-
tion (Ambion DNAse kit) and cDNA was synthesized with an Invitrogen First strand cDNA synthesis kit. Real 
time PCR was carried out on an ABI 7900HT thermocycler and relative transcript levels were calculated by the 
ΔΔCt method using GAPDH as an internal control to which all transcripts were normalized.
Injections and treatments. Indicated doses of LPS (Sigma) (5-50 mg/kg) were intra-peritoneally injected. 
For inflammatory models, mice were fed a high fat diet (23% fat, 0.1% carbohydrates, cholesterol pellets) 
(Specialty Feeds) for indicated time periods. For the induction of inflammatory bowel disease, mice received 
3% dextran sodium sulphate (DSS) (molecular mass 50KDa, MP Pharmaceuticals) in their drinking water for 5 
consecutive days followed by regular drinking water for 3 days. DSS/water was replaced with fresh DSS on Day 3.
Mice were treated with the GSTO1-1 inhibitor ML175 (10 mg/kg in ethanol/Cremophore EL 1:1 at −48, −24, 
and −2 hours prior to ip LPS injection (15 mg/kg). Cells treated with varied concentrations of ML175 in DMSO 
(0.25 μM- 5 μM) where indicated for 2 hours prior to LPS stimulation.
Glucose tolerance test (GTT) and Insulin tolerance test (ITT). GTT and ITT were performed after 12 
and 13 weeks on HFD respectively. For GTT, the mice were fasted for 16 hours and then injected intra-peritoneally 
with 1 g/kg glucose solution. For ITT, the mice were fasted for 6 hours and then injected with 1 IU/kg insulin 
intra-peritoneally. Blood glucose levels were determined at indicated time points using a FreeStyle Optium Xceed 
blood glucose meter.
Isolation and culture of primary adipocytes. Adipose tissue (3 g) was finely minced into sterile tubes 
and incubated for 1 hour at 37 °C in DMEM supplemented with 25 mm HEPES, 4 mg/ml collagenase type II, 
and 40 mg/ml albumin. Digested tissues were filtered through nylon mesh under sterile conditions and the cell 
suspension was centrifuged at 100 rpm for 5 minutes. The floating cells (upper pale layer) were collected and 
washed in DMEM supplemented with 10 mm HEPES, 20% FBS, 1% BSA and penicillin/streptomycin/neomy-
cin. 105 cells were seeded in 6-well plates and covered with a coverslip and cultured for 10 days at 37 °C, 5%CO2. 
The lipid content in cells was quantified by staining with Oil Red O. Cells were fixed with 10% formaldehyde for 
10 minutes at room temperature followed by washes in 60% isopropanol. Cells were stained with 0.2% oil red O 
staining solution for 10 minutes at room temperature followed by four washes in distilled water. The stain was 
eluted by incubating the cells in absolute isopropanol for 10 minutes. Supernatants were collected and absorbance 
was measured at 500 nm.
Flow cytometry. Adipose tissue was prepared as above. Cells were washed three times in PBS/1% FBS and 
blocked with FCblock followed by staining with F4/80-APC and Propidium iodide for 30 minutes at 4 °C. Cell 
preparations were analysed on a FACS Calibur.
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Clinical score. Clinical scores were assigned to DSS treated mice based on body weight, presence of faecal 
occult blood, stool consistency and blood in orifice which were determined daily for 8 days. Scoring was per-
formed blind by an independent observer.
Weight loss: No weight loss was given a score of 0, a loss of 1% from baseline (weight on Day 0) was a 1, loss of 
5–10% was a 2, loss of 10–20% was a 3 and a loss of >20% as a 4. Bleeding from orifice: No presence of blood at the 
anal orifice was scored as 0, mild redness as 1, positive for occult blood as 2, mild bleeding as 3 and gross bleeding 
as 4. Stool consistency: Normal, well-formed pellets were scored as 0, pasty pellets as 1, pasty and semi-formed 
pellets that do not adhere to the anus as 2, pasty and semi-formed pellets that do adhere to the anus as 3 and 
liquid stool that adheres to the anus as 4. Faecal occult blood: Blood in the faeces was determined daily using a 
ColoScreen Occult Blood Test (Helena Laboratories). A score of 1 was assigned if the screen turned pale blue and 
a score of 2 if the screen turned deep blue.
Isolation of mesenteric nodes and culture of gut flora. Mesenteric nodes were dissected into sterile 
PBS and homogenized using a micro pestle under sterile conditions. Cells were suspended in sterile Luria broth 
(LB) without antibiotic selection and plated on LB plates overnight (12 hours) at a 106 dilution. Colonies were 
counted by naked eye and scored as number of colonies/ml of cell suspension.
Proliferation assay. Proliferation of intestinal epithelial cells at the proximal, mid and distal sections of 
the colon was measured using a 5-bromo-2′-deoxyuridine (BrdU) Staining Kit (Life technologies). Mice were 
injected intraperitoneally with BrdU (10 ml/kg) 2 hours prior to harvesting organs. BrdU was detected immu-
nohistochemically on formalin fixed colon sections according to the manufacturer’s instructions. Images were 
captured using an Olympus IX71 inverted brightfield/fluorescence microscope. PCNA and c-myc were quantified 
by immuno blotting.
Tissue pathology. All histopathology was undertaken blind by an independent pathologist. Following fix-
ation in 10% neutral buffered formalin the tissues were processed into paraffin blocks using routine laboratory 
methods and 4 µm sections examined following routine hematoxylin-eosin (H&E) staining.
To examine the progression of the pathology associated with LPS mediated inflammation in Gsto1+/+ and 
Gsto1−/− mice were injected with 50 mg/kg LPS and euthanized at different time points (0.5, 1, 3, 6 and 12 hours) 
N = 3/time point. The liver and the spleen were examined with and without LPS treatment. The type and location 
of inflammatory cells were assessed. The amount of inflammation, necrosis and steatosis in the liver was graded 
as absent, mild, moderate or severe. The number of tingable body macrophages and neutrophils in the spleen was 
graded as absent, mild, moderate or marked increase.
The liver and adipose tissue were examined following a high fat diet for 13 weeks. The type and location of 
inflammatory cells were assessed. The amount of inflammation and steatosis in the liver was graded as absent, 
mild, moderate or severe.
Colons were examined following DSS treatment for 5 days. Following fixation the preparation of 4 µm H&E 
stained sections as described above, the type and location of inflammatory cells (colitis) was assessed by micros-
copy. The severity of the acute inflammation was graded as absent, mild, moderate (presence of mucosal erosions) 
or severe (presence of mucosal ulceration). The amount of chronic inflammation was graded as absent, mild, 
moderate or severe.
Cytokine measurement. The blood and the lungs were collected for cytokine measurement. The plasma 
was collected from the red blood cells by ultracentrifugation (16,000 rpm for 10 minutes). The lungs were mashed 
through a 70 µm cell strainer (BD Biosciences) and the supernatant collected into PBS. The level of IL-1ß, IL-6, 
and TNF-α were measured using a mouse ELISA kit (Elisakits.com, Australia) according to the manufacturer 
instructions.
Crystal structure of GSTO1-1with ML175. GSTO1-1 was crystallized as described previously1. Grains 
of solid compound ML175 was seeded into a drop containing crystals and allowed to equilibrate for 2 weeks. 
Crystals were transferred to a cryoprotectant solution comprised of 50 mM sodium acetate pH 4.6, and 1.0–
1.2 M (NH4)2SO4 and 5% glycerol prior to flash-cooling to 100 K. X-ray data were collected to 2.25 Å resolu-
tion using a Rigaku 007 HF X-ray Generator producing CuKα X-rays with Varimax optics. X-ray diffraction 
patterns were collected using a Mar345 desktop beamline. Diffraction data were integrated, merged and scaled 
with the HKL2000 package59. The structure was solved by PHASER60, using the structure of GSTO1-1 in com-
plex with GSH (PDB ID 1EEM). Iterative cycles of model building and refinement were performed in COOT61 
and REFMAC562. Electron density in 2mFo-DFc and mFo-DFc electron density maps was interpreted as bound 
ML175 and included in the model. X-ray data and model quality are given in Supplementary Table 1 and the 
coordinates for the present structure have been submitted to the protein data bank (ID 5V3Q).
ALARM NMR Assay. In brief, test compounds (400 μM final concentration) were incubated with 
13C-methyl-labelled La antigen (50 μM final concentration) at 37 °C for 1 h and then 30 °C for 15 h prior to data 
collection. Each compound was tested in the absence and presence of 20 mM DTT. Data were normalized to 
DMSO vehicle control. Data were recorded at 25 °C on a Bruker 700 MHz NMR spectrometer equipped with a 
cryoprobe (Bruker) and autosampler. Samples were acquired with 16 scans, 2048 complex points in F2, and 80 
points in F1 using standard protein HMQC and water suppression pulse sequences. Nonreactive compounds 
were identified by the absence of chemical shifts (13C-methyl) independent of the presence of DTT. Reactive 
compounds were identified by characteristic chemical shifts and peak attenuations in the absence of DTT25,26.
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Statistical analysis. Data were expressed as the mean ± standard error and analysed using Prism 4 
(Graphpad software Inc.). Statistical significance was calculated by standard t-tests or by Mann-Witney non par-
ametric tests between Gsto1−/− and WT groups. ANOVA with Tukey’s test was used where comparisons between 
multiple groups/treatments were made. For Kaplan Meier survival curves P values were determined by the 
Gehan-Breslo-Wilcox test comparing two curves at a time. P values were then adjusted for multiple comparisons 
by the Holm-Sidak method. All experiments were performed in triplicate unless otherwise stated.
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